Amgen, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Clinical Trials
1.2k
Trial Phases
6 Phases
Drug Approvals
3
Clinical Trials
Distribution across different clinical trial phases (1015 trials with phase data)• Click on a phase to view related trials
A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2025-09-15
- Last Posted Date
- 2025-09-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 14
- Registration Number
- NCT07172919
A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-09-08
- Last Posted Date
- 2025-09-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 70
- Registration Number
- NCT07160257
- Locations
- 🇺🇸
ProSciento, Chula Vista, California, United States
A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Teprotumumab (AMG 632) Administered Intravenously in Healthy Chinese Participants
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-08-27
- Last Posted Date
- 2025-09-22
- Lead Sponsor
- Amgen
- Target Recruit Count
- 20
- Registration Number
- NCT07142642
- Locations
- 🇨🇳
Huashan Hospital, Fudan University, Minhang, Shangai, China
Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients
- First Posted Date
- 2025-08-27
- Last Posted Date
- 2025-09-12
- Lead Sponsor
- Amgen
- Target Recruit Count
- 115
- Registration Number
- NCT07143513
- Locations
- 🇨🇳
Boao Evergrande International Hospital, Qionghai, Hainan, China
🇨🇳Boao Super Hospital, Qionghai, Hainan, China
🇨🇳Ruijin-Hainan Hospital Shanghai Jiao Tong University School of Medicine Hainan Boao Research Hospital, Qionghai, Hainan, China
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
- Conditions
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Interventions
- First Posted Date
- 2025-08-26
- Last Posted Date
- 2025-09-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 60
- Registration Number
- NCT07140900
- Locations
- 🇦🇺
Chris OBrien Lifehouse, Camperdown, New South Wales, Australia
🇦🇺Calvary Mater Newcastle Hospital, Waratah, New South Wales, Australia
🇨🇭Kantonsspital Graubuenden, Chur, Switzerland
- Prev
- 1
- 2
- 3
- 4
- 5
- 182
- Next
News
Crystalys Therapeutics Emerges with $205M Series A to Advance Gout Treatment Dotinurad
Crystalys Therapeutics launched with $205 million in Series A funding to develop dotinurad, a URAT1 blocker for gout treatment that is already approved in Japan, China, Philippines, and Thailand.
AstraZeneca's Tezspire Receives EU Regulatory Recommendation for Chronic Rhinosinusitis with Nasal Polyps
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of AstraZeneca and Amgen's Tezspire (tezepelumab) for treating chronic rhinosinusitis with nasal polyps in adults.
EMA Recommends Amgen's Uplizna for Rare Autoimmune Disease IgG4-RD
The European Medicines Agency's human medicines committee has recommended expanding Amgen's Uplizna (inebilizumab) indication to treat adult patients with active immunoglobulin G4-related disease (IgG4-RD).
Alnylam Pharmaceuticals Joins Alliance for Genomic Discovery to Accelerate RNAi Drug Development
Alnylam Pharmaceuticals has joined the Alliance for Genomic Discovery as the ninth member, gaining access to a comprehensive clinical genomic database containing 250,000 whole-genomes to accelerate RNA interference therapeutic development.
Ollin Biosciences Emerges with $100M to Challenge Leading Eye Disease Treatments
Ollin Biosciences launched with $100 million in Series A funding led by ARCH Venture Partners, Mubadala Capital, and Monograph Capital to develop next-generation ophthalmology treatments.
Dualitas Therapeutics Emerges from Stealth with $65M Series A to Advance Bispecific Antibody Pipeline
Dualitas Therapeutics launched from stealth with $65 million Series A funding co-led by Versant Ventures and Qiming Venture Partners USA, with participation from Eli Lilly and Company and other strategic investors.
Australian Court Denies Preliminary Injunction Against Sandoz Aflibercept Biosimilar Launch
The Federal Court of Australia denied Regeneron and Bayer's preliminary injunction application against Sandoz's aflibercept biosimilars, allowing the launch of Afqlir and Enzeevu to proceed as planned.
ALX Oncology Appoints Barbara Klencke as Interim Chief Medical Officer to Advance Cancer Pipeline
ALX Oncology has appointed Dr. Barbara Klencke as Interim Chief Medical Officer, replacing Dr. Alan Sandler who will return to the company's Board of Directors.
Samsung Biologics Secures $1.3 Billion US Manufacturing Deal Amid Trade Policy Uncertainty
Samsung Biologics has signed a $1.3 billion production contract with an unnamed US pharmaceutical company, extending through 2029.
Scenic Biotech Appoints Dr. Roland W. Bürli as Chief Scientific Officer to Advance Modifier Therapy Pipeline
Scenic Biotech has appointed Dr. Roland W. Bürli as Chief Scientific Officer, effective September 1, 2025, to lead the development of first-in-class modifier therapies for neurodegenerative and metabolic diseases.